Role of aGVHD Biomarkers on aGVHD Risks

  • STATUS
    Recruiting
  • participants needed
    500
  • sponsor
    Chinese PLA General Hospital
Updated on 19 February 2024
hematologic malignancies
allogeneic hematopoietic stem cell transplantation

Summary

To establish risk rating criteria of biological protein marker, determine the role and consistency of aGVHD biomarkers in aGVHD diagnosis and aGVHD prognosis, and evaluate the the impact on non-relapse mortality and relapse and disease free survival, the multicenter study on aGVHD biomarkers detection in the patients underwent allogeneic hematopoietic stem cell transplantation was performed.

Description

  1. To establish standard risk rating criteria of aGVHD biomarkers;
  2. To verify the role of aGVHD biomarkers monitored in predicting aGVHD risks;
  3. To determine the correlation between aGVHD biomarkers monitored and aGVHD risk;
  4. To carry out a observative study in patients with aGVHD treatment about therapeutic protocols and medication efficacy;
  5. To predict the correlation between the high-risk patients with aGVHD and non-relapse mortality and disease free survival;

Details
Condition Biological Markers, GVHD,Acute
Age 65years or below
Treatment aGVHD biomarker
Clinical Study IdentifierNCT04284904
SponsorChinese PLA General Hospital
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Diagnosed with hematological diseases
Have underwent first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies

Exclusion Criteria

recipients of second allogeneic stem cell transplant
pregnant or breast-feeding women
Serum creatinine > 2.0 mg/dL or creatinine clearance < 40 mL/min measured or calculated by Cockroft-Gault equation
human immunodeficiency virus infection
active hepatitis b virus, hepatitis C virus infection and need antivirus treatment
Subjects with evidence of relapsed primary disease, or subjects who have been treated for relapse after the allo-HSCT was performed, or graft rejection
allergic history to Janus kinase inhibitors
Severe organ dysfunction unrelated
Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.